Article Information
History
- September 23, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Emily Dorothee Meyer*,1,2,3,
- Mirco Sandfort1,2,3,
- Jennifer Bender3,4,5,
- Dorothea Matysiak-Klose6,
- Achim Dörre1,
- Gerhard Bojara7,
- Konrad Beyrer8 and
- Wiebke Hellenbrand6
- 1Department of Infectious Disease Epidemiology, Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute, Berlin, Germany
- 2European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- 4Department of Infectious Diseases, Nosocomial Pathogens and Antibiotic Resistances Unit, Robert Koch Institute, Berlin, Germany
- 5European Programme for Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- 6Department of Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany
- 7Local Public Health Authority Osnabrück
- 8Department of Infectious Diseases, Public Health Agency of Lower Saxony
- ↵*Corresponding author:
Emily Dorothee Meyer, Corresponding author email:
meyere{at}rki.de
↵3 These authors contributed equally to this article and share first authorship
Posted September 23, 2021.
Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-March 2021
